Peter Lawson is ranked #1819 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Peter Lawson (Barclays) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Peter Lawson's stock ratings?

About 59% of Peter's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Peter Lawson

BARC

Peter Lawson

Barclays

Wall Street Analyst

★★☆☆☆

#1819

on 13Foresight · ranked by our own returns

59%

Success Rate

+2.2%

Average Return

27 of 46 calls profitable · -9.0% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 59% of Peter Lawson's ratings turned a profit when each position was held for 1 year — averaging +2.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

71 Buy 12 Hold 2 Sell

Peter's Stock Coverage 54 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
RLAY Relay Therapeutics	Nov 24, 2025	BUY	Strong Buy +26.4% avg upside 19 analysts	$17.00 7.15% Upside	+94.0%
TCRX TScan Therapeutics	Nov 04, 2025	BUY	Strong Buy +823.9% avg upside 12 analysts	$3.00 226.09% Upside	-19.7%
TNGX Tango Therapeutics	Nov 04, 2025	BUY	Strong Buy +24.3% avg upside 14 analysts	$13.00 53.54% Downside	+303.1%
IDYA IDEAYA Biosciences	Nov 04, 2025	BUY	Strong Buy +55.2% avg upside 29 analysts	$40.00 28.14% Upside	+2.6%
IOVA Iovance Biotherapeutics	Nov 04, 2025	BUY	Strong Buy +225.8% avg upside 24 analysts	$4.00 2.28% Upside	+89.6%
KPTI Karyopharm Therapeutics	Nov 04, 2025	BUY	Strong Buy +147.4% avg upside 18 analysts	$10.00 10.82% Upside	+35.8%
INCY Incyte	Nov 04, 2025	BUY	Buy +1.0% avg upside 47 analysts	$101.00 2.81% Upside	-3.8%
GERN Geron	Nov 03, 2025	BUY	Strong Buy +239.8% avg upside 19 analysts	—	+19.2%
NUVL Nuvalent	Oct 31, 2025	BUY	Buy -0.3% avg upside 21 analysts	$112.00 9.27% Downside	+24.2%
BCYC Bicycle Therapeutics	Oct 31, 2025	BUY	Strong Buy +505.6% avg upside 20 analysts	$15.00 274.90% Upside	-46.0%
RCUS Arcus Biosciences	Oct 28, 2025	BUY	Strong Buy +38.0% avg upside 20 analysts	$14.00 42.46% Downside	+21.3%
FATE Fate Therapeutics	Oct 28, 2025	BUY	Buy +475.7% avg upside 31 analysts	$2.00 4.29% Downside	+32.9%
RVMD Revolution Medicines	Oct 23, 2025	BUY	Strong Buy -12.3% avg upside 32 analysts	$72.00 55.87% Downside	+195.2%
NRIX Nurix Therapeutics	Oct 23, 2025	BUY	Strong Buy +75.6% avg upside 26 analysts	$31.00 76.55% Upside	+69.1%
REPL Replimune Group	Oct 21, 2025	HOLD	Hold +72.3% avg upside 13 analysts	$3.00 70.65% Downside	+25.8%
SNDX Syndax Pharmaceuticals	Oct 16, 2025	BUY	Strong Buy +88.8% avg upside 27 analysts	$19.00 0.08% Downside	+21.7%
SDGR Schrodinger	Oct 06, 2025	BUY	Strong Buy +79.8% avg upside 14 analysts	$24.00 52.38% Upside	-32.1%
ONC BeOne Medicines	Sep 18, 2025	BUY	Strong Buy +28.4% avg upside 28 analysts	$385.00 42.51% Upside	-23.4%
KURA Kura Oncology	Sep 18, 2025	BUY	Strong Buy +161.3% avg upside 26 analysts	$11.00 10.74% Upside	+13.4%
BMEA Biomea Fusion	Sep 16, 2025	HOLD	Strong Buy +1037.0% avg upside 15 analysts	—	-27.7%
ADAPY Adaptimmune Therapeutics	Aug 14, 2025	SELL	Buy +5712.5% avg upside 10 analysts	$0.46 1050.02% Upside	·
CTMX CytomX Therapeutics	Aug 13, 2025	BUY	Strong Buy +269.6% avg upside 21 analysts	$3.50 18.57% Upside	+69.6%
IMCR Immunocore Holdings	Aug 08, 2025	BUY	Strong Buy +124.3% avg upside 22 analysts	$52.00 81.85% Upside	-12.3%
XNCR Xencor	Aug 07, 2025	SELL	Strong Buy +159.9% avg upside 27 analysts	$6.00 52.55% Downside	-54.0%
ARVN Arvinas Holding Company	Aug 07, 2025	BUY	Buy +264.5% avg upside 27 analysts	$16.00 108.55% Upside	+21.5%
EXEL Exelixis	Jul 29, 2025	HOLD	Strong Buy -21.0% avg upside 33 analysts	$40.00 23.04% Downside	+43.8%
MGNX MacroGenics	May 14, 2025	BUY	Buy +326.2% avg upside 25 analysts	$3.00 27.34% Downside	+168.4%
PRLD Prelude Therapeutics	May 07, 2025	SELL	Buy +151.3% avg upside 7 analysts	$1.00 76.92% Downside	-574.1%
NEXI NexImmune	Aug 16, 2022	BUY	Buy +7499900.0% avg upside 4 analysts	$2.00 1999900.02% Upside	·
NKTR Nektar Therapeutics	Mar 14, 2022	BUY	Buy +16.5% avg upside 25 analysts	$7.00 88.44% Downside	-71.2%
AGIO Agios Pharma	Apr 30, 2021	BUY	Strong Buy +73.2% avg upside 29 analysts	$70.00 104.89% Upside	-60.6%
CBIO Crescent Biopharma	Aug 05, 2019	HOLD	Strong Buy +26.9% avg upside 17 analysts	$5.00 71.80% Downside	·
COGT Cogent Biosciences	Jul 03, 2019	BUY	Strong Buy +7.1% avg upside 26 analysts	$6.00 82.54% Downside	-80.0%
TGTX TG Therapeutics	Mar 05, 2019	BUY	Strong Buy -34.4% avg upside 19 analysts	$15.00 71.80% Downside	·
AFMDQ Affimed	Nov 07, 2018	BUY	Buy +12648900.0% avg upside 15 analysts	$7.00 6999900.09% Upside	·
CRIS Curis	Aug 03, 2018	BUY	Strong Buy +1932.2% avg upside 12 analysts	$8.00 1800.31% Upside	+34.3%
CRSP Crispr Therapeutics AG	Mar 08, 2018	BUY	Buy +39.1% avg upside 41 analysts	$65.00 20.16% Upside	-29.8%
EDIT Editas Medicine	Jan 22, 2018	BUY	Buy +407.9% avg upside 33 analysts	$45.00 1572.88% Upside	-39.5%
CLLS Cellectis SA	Nov 07, 2017	HOLD	Strong Buy +573.5% avg upside 16 analysts	$28.00 839.65% Upside	+0.4%
LAB Standard BioTools	Sep 14, 2015	HOLD	Strong Buy +645.1% avg upside 8 analysts	—	-30.0%
CDNA CareDx	Sep 14, 2015	HOLD	Buy +25.1% avg upside 16 analysts	—	-37.5%
PGEN Precigen	Sep 14, 2015	HOLD	Buy +404.8% avg upside 11 analysts	—	·
VSTM Verastem	Sep 14, 2015	HOLD	Strong Buy +260.2% avg upside 23 analysts	—	-79.3%
TMO Thermo Fisher	Sep 14, 2015	HOLD	Strong Buy +26.8% avg upside 38 analysts	—	+21.5%
RVTY Revvity	Sep 14, 2015	HOLD	Buy +5.2% avg upside 23 analysts	—	+9.4%
OSUR Orasure Technologies	Sep 14, 2015	HOLD	Buy +100.0% avg upside 11 analysts	—	·
ILMN Illumina	Sep 14, 2015	HOLD	Buy -10.1% avg upside 30 analysts	—	-16.6%
BRKR Bruker	Sep 14, 2015	HOLD	Buy -7.0% avg upside 22 analysts	—	+23.4%
TCRT Alaunos Therapeutics	Jun 10, 2015	HOLD	Buy +604.3% avg upside 13 analysts	$10.00 365.21% Upside	-35.7%
MYGN Myriad Genetics	Feb 04, 2015	HOLD	Hold +313.3% avg upside 24 analysts	$32.00 604.90% Upside	+4.2%
WAT Waters	Oct 21, 2013	HOLD	Strong Buy +3.6% avg upside 30 analysts	$105.00 70.41% Downside	+0.9%
BDX Becton Dickinson	Aug 01, 2013	HOLD	Buy +35.5% avg upside 25 analysts	$100.00 30.53% Downside	+14.8%
QGEN Qiagen	Jul 31, 2013	HOLD	Buy +14.1% avg upside 23 analysts	$21.00 43.12% Downside	+16.9%
BGMD BG Medicine	May 10, 2013	HOLD	Hold +299999899.9% avg upside 2 analysts	$3.00 299999899.94% Upside	·

🔒 49 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Peter Lawson — Frequently Asked Questions

How accurate are Peter Lawson's stock ratings?

Based on the calls 13Foresight could measure, about 59% of Peter's ratings were profitable over a one-year hold, with an average return of +2.2% per rating, or -9.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Peter ranked on 13Foresight?

Peter Lawson is currently ranked #1819 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Peter cover?

Peter most recently has ratings on RLAY, TCRX, TNGX, IDYA, IOVA, KPTI, INCY, GERN, NUVL, BCYC, RCUS, FATE and 42 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!